Manual práctico de Trombosis y Hemostasia de la SETH

I I . PA T O LO G Í A D E L A H E M O ST A S I A — 7 6 — 7. Batlle J, Pérez Rodríguez A, López Fernández MF. Classification of von Willebrand disease. In: Von Willebrand disease: Basic and clinical aspects. Ed. Federici A, Lee L, Berntorp E, Lillicrap D, Montgomery B. London:Wiley-Blackwell; 2011. p. 74-85. 8. Rodeghiero F, Tosetto A. ISTH/SSC bleeding assessment tool: A standardized questionnaire and a proposal for a new blee- ding score for inherited bleeding disorders. J Thromb Haemost 2010;8: 2063-5. 9. Sadler JE.Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003;15;101(6):2089-93. 10. Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppen- heim R, Di Paola J; von Willebrand factor Subcommittee of the Standardization and Scientific Committee of the International Society for Thrombosis and Haemostasis. Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. J Thromb Haemost 2015;13(7):1345-50. 11. Batlle J, Pérez-Rodríguez A, Corrales I, López-Fernández MF, Rodríguez-Trillo Á, Lourés E, et al. Molecular and clinical profile of vonWillebrand disease in Spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm.Thromb Haemost 2016;115(1):40-50. 12. Corrales I, Catarino S, Ayats J, Arteta D, Altisent C, Parra R, et al. High-throughput molecular diagnosis of von Willebrand di- sease by next generation sequencing methods. Haematologica 2012;97(7):1003-7. 13. PérezA,Vidal F,Corrales I,et al.Enfermedad de vonWillebrand.Ca- pítulo 28. En: Manual de genética hematológica “GENHEM APP”- SEHH Manual de genética hematológica“GENHEMAPP” - SEHH. Disponible en: www.sehh.es/es/ 14. Borrás N, Batlle J, Pérez-Rodríguez A, López-Fernández MF, Rodríguez-Trillo Á, Lourés E, et al. Molecular and clinical profile of vonWillebrand disease in Spain (PCM-EVW-ES): Comprehensive genetic analysis by next-generation sequencing of 480 patients. Haematologica 2017 (en prensa). Disponible en: http://www. haematologica.org/content/haematol/early/2017/09/21/haema- tol.2017.168765.full.pdf 15. Batlle J, Pérez-Rodríguez A, Corrales I, Pinto JC, Fraga EL, Rodríguez-Trillo Tch A, et al. Diagnosis and management of vonWillebrand disease in Spain.Annals of Blood 2017 (en prensa). 16. Batlle J, Altisent C, Aznar JA, et al.Tratamiento de la enfermedad deVonWillebrand en España. Documento de consenso. Haema- tologica 2012; 97:1-23. Disponible en: http://www.seth.es 17. Laffan MA, Lester W, O’Donnell JS, Will A, Tait RC, Goodeve A, el al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol 2014; 167(4):453-65. 18. Franchini M, Mannucci P.Von Willebrand factor (Vonvendi ® ): the first recombinant product licensed for the treatment of vonWi- llebrand disease. Expert Review of Hematology 2016. http://dx. doi.org/10.1080/17474086.2016.1214070 19. Singal M, Kouides PA. Recombinant von Willebrand factor: a first-of-its-kind product for von Willebrand disease. Drugs Today (Barc) 2016; 52:653-64.